相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Experts at the 2025 World Conference on Genitourinary Cancers discussed specialized treatment strategies for variant histologies in prostate, bladder, and kidney cancers, including small cell and neuroendocrine differentiation subtypes. - The conference emphasized the importance of risk stratification tools like Decipher Prostate scores, MRI scans, and PSA levels for optimizing surveillance and treatment decisions in community oncology settings. - Novel therapeutic combinations such as enfortumab vedotin-ejfv plus pembrolizumab for bladder cancer variants and the development of new intravesical therapies were highlighted as expanding treatment options. - Multidisciplinary collaboration between medical oncologists and urologists was identified as crucial for managing complex genitourinary malignancies and implementing appropriate surveillance strategies in community practice.
- Clinical trial participation faces major barriers, with trial unavailability and lack of physician referrals identified as primary obstacles to patient enrollment in research studies. - Vanderbilt's NCI-designated cancer center is implementing AI-driven screening systems to match eligible patients with clinical trials, addressing the challenge of comprehensive patient screening. - The Meharry-Vanderbilt Alliance, partnering with a historically Black medical institution, focuses on building community trust and expanding trial access through education and local support networks.
- Dr. Karen Winkfield, Ingram Professor at Vanderbilt, highlights the critical need to recognize healthcare is not one-size-fits-all, especially for underserved communities facing unique access challenges. - Healthcare providers must focus on relationship building and cultural humility to establish trust with diverse patient populations and ensure effective cancer care delivery. - Community engagement and clear communication of medical research are essential for building public trust and ensuring equitable access to cancer treatment innovations.
